NEXGEL (NXGL) Stock Price, News & Analysis

Company Overview

NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.

Key Stats

• Today's Range: $2.62 to $2.90
• 50-Day Range: $2.54 to $3.62
• 52-Week Range: $1.84 to $5.10
• Volume: 21,515 shs
• Average Volume: 65,500 shs
• Market Capitalization: $21.66 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NEXGEL Stock Analysis - MarketRank™

NEXGEL scored higher than 10% of companies evaluated by MarketBeat, and ranked 883rd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for NEXGEL.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of NEXGEL is -4.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NEXGEL is -4.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

NEXGEL has a P/B Ratio of 3.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.52% of the float of NEXGEL has been sold short.

Short Interest Ratio / Days to Cover

NEXGEL has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NEXGEL has recently increased by 42.37%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NEXGEL does not currently pay a dividend.

Dividend Growth

NEXGEL does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.52% of the float of NEXGEL has been sold short.

Short Interest Ratio / Days to Cover

NEXGEL has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NEXGEL has recently increased by 42.37%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: -0.03

News Sentiment

NEXGEL has a news sentiment score of -0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for NEXGEL this week, compared to 1 article on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, NEXGEL insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $65,490.00 in company stock.

Percentage Held by Insiders

24.86% of the stock of NEXGEL is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 2.21% of the stock of NEXGEL is held by institutions.

NXGL Stock Analysis - Frequently Asked Questions

How have NXGL shares performed this year?

NEXGEL's stock was trading at $4.46 at the beginning of the year. Since then, NXGL shares have decreased by 36.5% and is now trading at $2.83.
View the best growth stocks for 2025 here.

How were NEXGEL's earnings last quarter?

NEXGEL, Inc. (NASDAQ:NXGL) announced its quarterly earnings data on Monday, March, 24th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.02. The company earned $3.04 million during the quarter, compared to analyst estimates of $2.99 million. NEXGEL had a negative net margin of 52.60% and a negative trailing twelve-month return on equity of 71.19%.
Read the conference call transcript.

When did NEXGEL IPO?

NEXGEL (NXGL) raised $14 million in an initial public offering on Wednesday, December 22nd 2021. The company issued 2,100,000 shares at a price of $6.83 per share. Maxim Group LLC served as the underwriter for the IPO.

How do I buy shares of NEXGEL?

Shares of NXGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NEXGEL own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NEXGEL investors own include Lexicon Pharmaceuticals (LXRX), Aditxt (ADTX), Helius Medical Technologies (HSDT), Onconova Therapeutics (ONTX), EchoStar (SATS), American Battery Technology (ABML) and Aumann (AAG).

Company Calendar

• Last Earnings: 3/24/2025
• Today: 4/17/2025
• Next Earnings (Estimated): 5/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:NXGL
• CIK: 1468929
• Web: nexgel.com
• Phone: 215-702-8550
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-3,160,000.00
• Net Margins: -52.60%
• Pretax Margin: -56.85%
• Return on Equity: -71.19%
• Return on Assets: -34.79%

Debt

• Debt-to-Equity Ratio: 0.19
• Current Ratio: 1.51
• Quick Ratio: 0.93

Sales & Book Value

• Annual Sales: $8.69 million
• Price / Sales: 2.49
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.90 per share
• Price / Book: 3.14

Miscellaneous

• Outstanding Shares: 7,654,000
• Free Float: 5,103,000
• Market Cap: $21.66 million
• Optionable: Not Optionable
• Beta: 0.63